

Company Number: 559678

Alphamed Consulting Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 March 2025

Alphamed Consulting Limited

CONTENTS

	Page
Directors and Other Information	3
Directors' Responsibilities Statement	4
Balance Sheet	5
Reconciliation of Shareholders' Funds	6
Notes to the Financial Statements	7 - 9

Alphamed Consulting Limited
DIRECTORS AND OTHER INFORMATION

Directors	Carmel McGrath Jennifer McGrath
Company Number	559678
Registered Office and Business Address	Knock, Barnaderg, Tuam Galway Ireland
Accountants	Meenaghan & Co Unit 44 N17 Business Park Galway Road Galway Republic of Ireland

Alphamed Consulting Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 March 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Carmel McGrath
Director

10 February 2026

Jennifer McGrath
Director

10 February 2026

Alphamed Consulting Limited

BALANCE SHEET

as at 30 March 2025

	Notes	Mar 25 €	Mar 24 €
Fixed Assets			
Tangible assets	4	25,738	25,738
Current Assets			
Debtors	5	31,463	37,743
Cash and cash equivalents		121,258	320,077
		152,721	357,820
Creditors: amounts falling due within one year	6	(6,579)	(23,090)
Net Current Assets		146,142	334,730
Total Assets less Current Liabilities		171,880	360,468
Capital and Reserves			
Called up share capital presented as equity		1	1
Retained earnings		171,879	360,467
Equity attributable to owners of the company		171,880	360,468

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Alphamed Consulting Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 10 February 2026 and signed on its behalf by:

Carmel McGrath
Director

Jennifer McGrath
Director

Alphamed Consulting Limited
RECONCILIATION OF SHAREHOLDERS' FUNDS

as at 30 March 2025

	Called up share capital €	Retained earnings €	Total €
At 31 March 2023	1	307,367	307,368
Profit for the financial year	-	53,100	53,100
At 30 March 2024	1	360,467	360,468
Loss for the financial year	-	(188,588)	(188,588)
At 30 March 2025	1	171,879	171,880

Alphamed Consulting Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 March 2025

1. General Information

Alphamed Consulting Limited is a company limited by shares incorporated in Ireland. Knock,, Barnaderg,, Tuam, Galway, Ireland is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

Statement of compliance

The financial statements of the company for the year ended 30 March 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-
-----------------------------	---

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

Alphamed Consulting Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 March 2025

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Employees

The average monthly number of employees, including directors, during the financial year was 2, (Mar 24 - 1).

	Mar 25 Number	Mar 24 Number
Directors	<u>1</u>	<u>1</u>

4. Tangible assets

	Land and buildings freehold €	Total €
Cost		
At 31 March 2024	<u>25,738</u>	<u>25,738</u>
At 30 March 2025	<u>25,738</u>	<u>25,738</u>
Depreciation		
At 31 March 2024	<u>-</u>	<u>-</u>
At 30 March 2025	<u>-</u>	<u>-</u>
Net book value		
At 30 March 2025	<u>25,738</u>	<u>25,738</u>
At 30 March 2024	<u>25,738</u>	<u>25,738</u>

5. Debtors

	Mar 25 €	Mar 24 €
Trade debtors	1,318	19,492
Other debtors	19,000	10,000
Directors' current accounts	8,713	5,821
Taxation	2,432	2,430
	<u>31,463</u>	<u>37,743</u>

Alphamed Consulting Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 March 2025

6. Creditors	Mar 25	Mar 24
Amounts falling due within one year	€	€
Amounts owed to credit institutions	2,699	1,732
Taxation	-	16,220
Accruals	3,880	5,138
	<u>6,579</u>	<u>23,090</u>
	<u><u>6,579</u></u>	<u><u>23,090</u></u>
 7. Income Statement		
	Mar 25	Mar 24
	€	€
At 31 March 2024	360,467	307,367
(Loss)/profit for the financial year	(188,588)	53,100
	<u>171,879</u>	<u>360,467</u>
At 30 March 2025	<u><u>171,879</u></u>	<u><u>360,467</u></u>
 8. Capital commitments		
The company had no material capital commitments at the financial year-ended 30 March 2025.		
 9. Directors' remuneration	Mar 25	Mar 24
	€	€
Remuneration	35,487	54,024
Pension contributions	207,200	-
	<u>242,687</u>	<u>54,024</u>
	<u><u>242,687</u></u>	<u><u>54,024</u></u>
 10. Post-Balance Sheet Events		
There have been no significant events affecting the company since the financial year-end.		
 11. Approval of financial statements		
The financial statements were approved and authorised for issue by the board of directors on 10 February 2026.		